Biotech | February 27, 2022
VBI’s 3-antigen Hepatitis B vaccine gets CHMP nod
If approved, PreHevbri will be the only approved 3-antigen hepatitis B vaccine for adults in the E.U.
If approved, PreHevbri will be the only approved 3-antigen hepatitis B vaccine for adults in the E.U.
Cantex also plans to initiate Phase 2 clinical trials exploring the therapeutic effect of azeliragon in pancreatic and breast cancers.
UNICOR-v has the potential to protect against future epidemics caused by a coronavirus jumping from animals to humans, but also against new variants emerging from SARS-Cov-2
100% efficacy against severe Covid-19 disease and hospitalizations
Methodology developed by QIMR Berghofer researchers utilizing the Agilent Cary 630 FTIR
As part of its on-going work to track variants, WHO's Technical Advisory Group on SARS-CoV-2 Virus Evolution (TAG-VE) discussed the latest evidence on the Omicron variant of concern
New biotechnology product aims to be world's fastest automatic sanitary solution
The researchers are of the view that the new drug designing strategy demonstrated by them could also be adopted to treat retroviral infections.
The grants are expected to be received over the next three years, commencing March 2022
These programs are: Herpes simplex virus (HSV) vaccine candidate, Varicella-zoster virus (VZV) vaccine candidate and Checkpoint cancer vaccine.
Subscribe To Our Newsletter & Stay Updated
